First Generation of peptide pharmaceuticals

The first generation of the platform was originally developed by Dr. V. Deigin’ team in the world-renowned Soviet Academic Shemyakin and Ovchinnikov Institute in the 1985-1990th.

In the 1980s, we developed the preparative HPLC-based multistep technology and carried out the work on the individual peptide isolation from the thymus homogenate and determining their chemical structure and biological activity.

The process of peptide isolation was conducted in 3 steps: separation of peptide pool of molecules from the crude organs, purification of active low molecular weight fraction, and identification of the individual peptides.

Exploring this technology, we invented and developed in collaboration with other scientists the first unique pharmaceutical, THYMOGEN – an immunomodulator approved for the treatment of immunodeficient-related diseases. THYMOGEN was patented in 15 world-leading countries and has been selling on the Russian market since 1990.